Skip to main content
Premium Trial:

Request an Annual Quote

James Mulshine, Nathaniel Berlin, Peter Klemm

Gene Express has appointed James Mulshine to its scientific advisory board. Mulshine, a former oncologist at the National Cancer Institute, now is associate provost for research at Rush University Medical Center in Chicago. At NCI, he was head of the Intervention Section of the Cell and Cancer Biology Department, Division of Clinical Sciences. He is a member of the American Society of Clinical Oncology, American Association of Cancer Research, International Association for the Study of Lung Cancer, and the American Federation of Clinical Research.

Nathaniel Berlin, former director of the National Cancer Institute’s division of Cancer Biology and Diagnosis, died this week in Florida at the age of 87, The Washington Post reported. Berlin also started and directed the Northwestern University Cancer Center and he was a professor of oncology and director of what became the Sylvester Comprehensive Cancer Center.

Predictive Biosciences has named Peter Klemm president and CEO, as well as a director of the company. Klemm previously was CEO of GeneOhm Sciences, and he was CEO of JOMED and senior VP of R&D at Gruennenthal. He also was a senior scientist at Aventis and a post-doctoral fellow at the William Harvey Research Institute.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.